Eli Lilly and Company: Cognitive Dysfunction trials
The registry lists 24 Cognitive Dysfunction studies with Eli Lilly and Company as lead sponsor. 5 are open to participants now and 16 have results posted.
Phase 1 7Phase 2 8Phase 3 6No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of LY3439539 in Participants With Alzheimer's DiseaseRecruitingNCT07598370Phase 1
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)RecruitingNCT07589595Phase 2
- A Study of Retinal Imaging to Detect Abnormal Protein Deposits Associated With Alzheimer's DiseaseRecruitingNCT07254234
- A Study Evaluating the Impact of P-tau217 Blood Biomarker Testing on Early Evaluation and Management of Patients Presenting With Cognitive ComplaintRecruitingNCT07140744Not applicable
- A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's DiseaseRecruitingNCT06297590Phase 1
- A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)CompletedNCT05108922Phase 3Results posted
- A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's DiseaseCompletedNCT05063539Phase 2Results posted
- A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)CompletedNCT04640077Phase 2Results posted
- Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's DiseaseCompletedNCT04468347Phase 1Results posted
- A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)Active, not recruitingNCT04437511Phase 3Results posted
- A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's DiseaseCompletedNCT03518073Phase 2Results posted
- Flortaucipir 18F PET Imaging in BIOCARD StudyTerminatedNCT03052972Phase 1Results posted
- A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)TerminatedNCT02614131Phase 1Results posted
- A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)CompletedNCT01662882Phase 2/3Results posted
- Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET ScansCompletedNCT01550549Not applicableResults posted
- A Study of LY2886721 in Healthy ParticipantsCompletedNCT01534273Phase 1Results posted
- Clinical Evaluation of Florbetapir F 18 (18F-AV-45)CompletedNCT01518374Phase 2Results posted
- A Non-drug Methods Study in Participants With Alzheimer's DiseaseCompletedNCT01459016Phase 1Results posted
- Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive DeclineCompletedNCT01400425Phase 3Results posted
- Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)CompletedNCT00857506Phase 2Results posted
- A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)CompletedNCT00702143Phase 2Results posted
- A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)Active, not recruitingNCT05508789Phase 3
- A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)CompletedNCT05463731Phase 3
- A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)Active, not recruitingNCT02951598